@article{4660120f8fff4009897c73b61186e763,
title = "Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey",
abstract = "BACKGROUND: Patients with psoriasis experience impairment in quality of life. Thus, high-quality dermatological care is of particular importance.PATIENTS AND METHODS: We performed a nationwide cross-sectional survey in Austria (BQSAustria Psoriasis 2014/2015) with a special focus on quality of life and satisfaction with treatment among psoriasis patients predominantly treated at tertiary care centers.RESULTS: Overall, 70.2 % of 1,184 patients reported impaired quality of life (DLQI 2-5: 29.4 %; 6-10: 19.3 %; 11-15: 11.5 %; 16-20: 5.2 % and > 20: 4.9 %) despite treatment over the preceding four weeks (topical treatment in 88.2 % of cases and/or systemic treatment in 38.7 %). On average, none of the 25 defined subjective treatment goals was achieved to a sufficient degree. In particular, 82.2 % of patients continued to have pruritus despite treatment, which was highly significantly associated with a poor general health status over the preceding week (Spearman's rank correlation; p = 1.1e-45), the extent of body surface area (p = 3.2e-11) and scalp area (p = 3.2e-11) affected, as well as pain (p = 2.3e-22). Treatment with a biologic was significantly correlated with higher patient satisfaction (Wilcoxon-Test, p = 2.0e-16).CONCLUSIONS: Despite dermatological care, the majority of Austrian psoriasis patients continues to experience impaired quality of life; there is potential for improvement in the achievement of treatment goals.",
keywords = "Austria, Cross-Sectional Studies, Humans, Pain, Pruritus, Psoriasis/complications, Quality of Life",
author = "Peter Wolf and Wolfgang Weger and Franz Legat and Clemens Painsi and Werner Saxinger and Robert M{\"u}llegger and Paul Sator and Gudrun Ratzinger and Sylvia Selhofer and Leo Richter and Wolfgang Salmhofer and Bernhard Lange-Asschenfeldt and Franz Trautinger and Alexander Mlynek and Robert Strohal and Matthias Augustin and Franz Quehenberger",
note = "Funding Information: P.W. has received research grants, honoraria as lecturer and/ or consultant, and/or travel grants from AbbVie, Almirall, Eli Lilly, Janssen, Leo Pharma, Merck Sharp & Dohme, and Pfizer. G.R. has received research grants, honoraria as lecturer and/or consultant, and/or travel grants from Abb-Vie, Eli Lilly, Celgene, Janssen, Leo Pharma, Novartis, and Pfizer. F.L. has received honoraria as lecturer and/or travel grants from AbbVie, Janssen, Leo Pharma, and Pfizer. P.S. has received research grants, honoraria as lecturer and/or consultant, and/or travel grants from AbbVie, Actelion, Am-gen, Almirall, Janssen, Novartis, Leo Pharma, Pfizer, Merck Sharp & Dohme, Celgene, Maruho, AbbVie, UCB, and Lilly. F.T. has received honoraria as lecturer from AbbVie, Pfizer, and Leo Pharma as well as honoraria as consultant from Eli Lilly, Novartis, Pfizer, and Leo. R.S. has given lectures for Pfizer, Novartis, and Eli Lilly. W.W. has received research grants, honoraria as lecturer and/or consultant, and/ or travel grants from AbbVie, Amgen, Eli Lilly, Janssen, Leo Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. Publisher Copyright: {\textcopyright} 2018 Deutsche Dermatologische Gesellschaft (DDG).",
year = "2018",
month = aug,
doi = "10.1111/ddg.13613",
language = "English",
volume = "16",
pages = "981--990, 981--991",
journal = "JDDG - Journal of the German Society of Dermatology",
issn = "1610-0379",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",
}